ID   LCLC-97TM1
AC   CVCL_1376
SY   LCLC97TM1
DR   CLO; CLO_0007283
DR   EFO; EFO_0006635
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03473042
DR   BioSample; SAMN03473572
DR   BioSample; SAMN10988572
DR   CCLE; LCLC97TM1_LUNG
DR   Cell_Model_Passport; SIDM00344
DR   ChEMBL-Cells; CHEMBL3308112
DR   ChEMBL-Targets; CHEMBL1075489
DR   CLS; 300409/p504_LCLC-97TM1
DR   Cosmic; 946361
DR   Cosmic; 1146948
DR   Cosmic; 1995482
DR   Cosmic-CLP; 946361
DR   DepMap; ACH-000596
DR   DSMZ; ACC-388
DR   GDSC; 946361
DR   GEO; GSM434288
DR   GEO; GSM784234
DR   GEO; GSM887265
DR   GEO; GSM888340
DR   GEO; GSM1670046
DR   IARC_TP53; 27176
DR   IGRhCellID; LCLC97TM1GEO
DR   LiGeA; CCLE_643
DR   LINCS_LDP; LCL-1782
DR   PharmacoDB; LCLC97TM1_834_2019
DR   PRIDE; PXD002556
DR   Progenetix; CVCL_1376
DR   Wikidata; Q54902346
RX   PubMed=2840315;
RX   PubMed=20164919;
RX   PubMed=22460905;
RX   PubMed=25485619;
RX   PubMed=26361996;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=31068700;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: NCI RAS program mutant KRAS cell line panel.
CC   Doubling time: 26 hours (PubMed=2840315); >50 hours (DSMZ).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (CCLE; Cosmic-CLP).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu35Cysfs*9 (c.102delC); ClinVar=VCV001072141; Zygosity=Heterozygous (CCLE; Cosmic-CLP).
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=4.96%; Native American=0.5%; East Asian, North=5.82%; East Asian, South=0%; South Asian=0%; European, North=49.41%; European, South=39.32% (PubMed=30894373).
CC   Misspelling: LCL97TM; In PubMed=26361996.
ST   Source(s): CLS; Cosmic-CLP; DSMZ; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 11,13
ST   D16S539: 12,13
ST   D18S51: 16
ST   D21S11: 27,30
ST   D3S1358: 15
ST   D5S818: 10,12
ST   D7S820: 10,10.2,11 (PubMed=25877200)
ST   D7S820: 10,11 (CLS; Cosmic-CLP; DSMZ)
ST   D8S1179: 14
ST   FGA: 23
ST   Penta D: 12,15
ST   Penta E: 15
ST   TH01: 8
ST   TPOX: 8,11
ST   vWA: 19,20
DI   NCIt; C4450; Lung large cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   44Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 23-09-21; Version: 31
//
RX   PubMed=2840315; DOI=10.1111/j.1432-0436.1988.tb00806.x;
RA   Bepler G., Koehler A., Kiefer P., Havemann K., Beisenherz K.,
RA   Jaques G., Gropp C., Haeder M.;
RT   "Characterization of the state of differentiation of six newly
RT   established human non-small-cell lung cancer cell lines.";
RL   Differentiation 37:158-171(1988).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=26361996; DOI=10.1016/j.jprot.2015.09.003;
RA   Grundner-Culemann K., Dybowski J.N., Klammer M., Tebbe A., Schaab C.,
RA   Daub H.;
RT   "Comparative proteome analysis across non-small cell lung cancer cell
RT   lines.";
RL   J. Proteomics 130:1-10(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//